CY1117107T1 - Θεραπεια του καρκινου με τον ογκολυτικο ιο της δαμαλιτιδας - Google Patents
Θεραπεια του καρκινου με τον ογκολυτικο ιο της δαμαλιτιδαςInfo
- Publication number
- CY1117107T1 CY1117107T1 CY20161100008T CY161100008T CY1117107T1 CY 1117107 T1 CY1117107 T1 CY 1117107T1 CY 20161100008 T CY20161100008 T CY 20161100008T CY 161100008 T CY161100008 T CY 161100008T CY 1117107 T1 CY1117107 T1 CY 1117107T1
- Authority
- CY
- Cyprus
- Prior art keywords
- vaccinia virus
- tumor
- oclitic
- dumalitid
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Οι ενσωματώσεις της εφεύρεσης είναι κατευθυνόμενες μέθοδοι που περιλαμβάνουν έναν ιό της δαμαλίτιδας με ανεπάρκεια στη θυμιδίνη κινάσης. Οι μέθοδοι περιλαμβάνουν τη χορήγηση του ιού της δαμαλίτιδας σε αυξημένες ιικές συγκεντρώσεις. Περαιτέρω απόψεις της εφεύρεσης περιλαμβάνουν μεθόδους για την επαγωγή ογκόλυσης ή κατάρρευσης της αγγείωσης του όγκου σε ένα υποκείμενο που έχει έναν όγκο η οποία περιλαμβάνει τη χορήγηση σε ένα υποκείμενο στο οποίο έχουν χορηγηθεί τουλάχιστον 1 x 108 ιικά σωματίδια ενός φορέα του ιού της δαμαλίτιδας με ανεπάρκεια σε ΤΚ, που εκφράζει GM-CSF, ικανού αντιγραφής ο οποίος ένας αρκετός για να επάγει την ογκόλυση κυττάρων σε έναν όγκο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89493207P | 2007-03-15 | 2007-03-15 | |
EP08732358.0A EP2136633B1 (en) | 2007-03-15 | 2008-03-17 | Oncolytic vaccinia virus cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1117107T1 true CY1117107T1 (el) | 2017-04-05 |
Family
ID=39760123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161100008T CY1117107T1 (el) | 2007-03-15 | 2016-01-08 | Θεραπεια του καρκινου με τον ογκολυτικο ιο της δαμαλιτιδας |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100303714A1 (el) |
EP (1) | EP2136633B1 (el) |
JP (2) | JP5879024B2 (el) |
KR (3) | KR20080084528A (el) |
CN (2) | CN101790310A (el) |
AU (1) | AU2008224811B2 (el) |
BR (1) | BRPI0808736A2 (el) |
CA (1) | CA2681096C (el) |
CY (1) | CY1117107T1 (el) |
DK (1) | DK2136633T3 (el) |
ES (1) | ES2559684T3 (el) |
HK (1) | HK1139563A1 (el) |
HR (1) | HRP20160041T1 (el) |
HU (1) | HUE028362T2 (el) |
PL (1) | PL2136633T3 (el) |
PT (1) | PT2136633E (el) |
SI (1) | SI2136633T1 (el) |
WO (1) | WO2008113078A1 (el) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2269618A1 (en) | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer. |
US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
KR20090004839A (ko) | 2005-09-07 | 2009-01-12 | 제네렉스, 인코포레이티드 | Gm-csf를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법 |
WO2009139921A2 (en) * | 2008-05-16 | 2009-11-19 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
DK2477499T3 (en) | 2009-09-14 | 2018-06-06 | Sillajen Biotherapeutics Inc | COMBINATION CANCER THERAPY WITH ONCOLYTIC VACCINIA VIRUS |
JP6121910B2 (ja) * | 2011-01-04 | 2017-04-26 | シラジェン バイオセラピューティクス インコーポレイテッド | 腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成 |
EP2697368B1 (en) | 2011-04-15 | 2019-06-05 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
CN103732236B (zh) * | 2011-08-05 | 2017-09-15 | 新罗杰公司 | 用于生产痘苗病毒的方法和组合物 |
US10140420B2 (en) * | 2011-10-12 | 2018-11-27 | Merge Healthcare Incorporation | Systems and methods for independent assessment of image data |
TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
KR101632897B1 (ko) * | 2013-04-10 | 2016-06-23 | 신라젠(주) | 백시니아 바이러스로부터 유래한 신규한 항암 바이러스 hbb301 |
LT3778897T (lt) | 2013-08-22 | 2024-02-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Imunoonkolitinės terapijos |
ES2768715T3 (es) * | 2014-04-10 | 2020-06-23 | Transgene | Vectores oncolíticos poxvíricos |
KR102504758B1 (ko) | 2014-07-16 | 2023-02-28 | 트랜스진 | 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물 |
KR101949849B1 (ko) * | 2014-07-17 | 2019-05-30 | 더 보드 오브 트러스티즈 오브 웨스턴 미시간 유니버시티 | 암세포를 치료하기 위한 조성물 및 그 방법 |
EP3186738A1 (en) | 2014-08-29 | 2017-07-05 | Koninklijke Philips N.V. | Handling undetermined quantifiable lesions |
AU2015357225B2 (en) | 2014-12-01 | 2020-04-09 | Transgene Sa | Stable liquid vaccinia virus formulations |
WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
US10548930B2 (en) | 2015-04-17 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors |
CA2990133A1 (en) * | 2015-06-19 | 2017-03-09 | Sillajen, Inc. | Compositions and methods for viral embolization |
CN107921096A (zh) * | 2015-07-30 | 2018-04-17 | 恩多技术公司 | 用于胰腺癌或结肠癌治疗的集落刺激因子 |
MX2018010231A (es) | 2016-02-25 | 2019-06-06 | Memorial Sloan Kettering Cancer Center | Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos. |
CN116440176A (zh) * | 2016-02-25 | 2023-07-18 | 纪念斯隆凯特琳癌症中心 | 具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
WO2017205674A1 (en) * | 2016-05-25 | 2017-11-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic vaccinia virus mutants and using same for cancer treatment |
CA3052463A1 (en) * | 2017-02-03 | 2018-08-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
US10575774B2 (en) | 2017-02-27 | 2020-03-03 | Case Western Reserve University | Predicting immunotherapy response in non-small cell lung cancer with serial radiomics |
ES2971065T3 (es) * | 2017-04-21 | 2024-06-03 | Sillajen Inc | Terapia de combinación de virus vaccinia oncolítica y un inhibidor de punto de control |
CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
KR20190059421A (ko) * | 2017-11-23 | 2019-05-31 | 주식회사 바이오녹스 | 항암바이러스의 간동맥 투여를 이용한 간암 치료방법 |
JP2021503965A (ja) | 2017-12-01 | 2021-02-15 | スッター,ゲルド | 複製効率の高い免疫調節ワクシニアウイルス株 |
SG11202006457YA (en) | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
WO2019168346A1 (ko) * | 2018-02-28 | 2019-09-06 | 주식회사 바이오녹스 | 항암바이러스 및 히드록시유레아를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
KR102661908B1 (ko) * | 2019-08-29 | 2024-04-29 | 주식회사 바이오녹스 | 백시니아 바이러스 및 과립백혈구 형성 억제제를 유효성분으로 포함하는 암 치료용 약학 조성물 |
EP4268837A1 (en) | 2020-12-22 | 2023-11-01 | Virocure, Inc. | Novel modified reovirus and use thereof |
KR20220122551A (ko) * | 2021-02-26 | 2022-09-02 | 신라젠(주) | 항암 바이러스 및 이의 용도 |
WO2024054040A1 (ko) * | 2022-09-07 | 2024-03-14 | 신라젠(주) | 항암 바이러스의 신규 용도 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
NL8200523A (nl) | 1982-02-11 | 1983-09-01 | Univ Leiden | Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna. |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5824311A (en) * | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
US4952500A (en) | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
US5151509A (en) * | 1988-12-16 | 1992-09-29 | United States Of America | Gene encoding serine protease inhibitor |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
US5798339A (en) | 1990-12-17 | 1998-08-25 | University Of Manitoba | Treatment method for cancer |
US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
DE69233169T2 (de) | 1991-11-15 | 2004-05-27 | Smithkline Beecham Corp. | Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor. |
EP0604662B1 (en) | 1992-07-07 | 2008-06-18 | Japan Tobacco Inc. | Method of transforming monocotyledon |
US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
EP0652965A1 (en) | 1992-07-27 | 1995-05-17 | Pioneer Hi-Bred International, Inc. | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
US5801029A (en) * | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
JP2935950B2 (ja) | 1993-12-03 | 1999-08-16 | 株式会社山田製作所 | ステアリングシャフト及びその製造装置 |
EP0758382A1 (en) * | 1994-04-29 | 1997-02-19 | Sidney Kimmel Cancer Center | Enhancing the sensitivity of tumor cells to therapies |
US5656465A (en) * | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
US6093700A (en) * | 1995-05-11 | 2000-07-25 | Thomas Jefferson University | Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF |
US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
AU713661B2 (en) * | 1995-09-29 | 1999-12-09 | Immunex Corporation | Chemokine inhibitor |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
DE19541450C2 (de) * | 1995-11-07 | 1997-10-02 | Gsf Forschungszentrum Umwelt | Genkonstrukt und dessen Verwendung |
US5739169A (en) * | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
US5846225A (en) | 1997-02-19 | 1998-12-08 | Cornell Research Foundation, Inc. | Gene transfer therapy delivery device and method |
ATE323170T1 (de) * | 1997-02-21 | 2006-04-15 | Oxxon Therapeutics Ltd | Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. |
US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
US6177076B1 (en) * | 1997-12-09 | 2001-01-23 | Thomas Jefferson University | Method of treating bladder cancer with wild type vaccinia virus |
EP2325321A1 (en) * | 1999-05-28 | 2011-05-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
US20040091995A1 (en) * | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
DE10134955C1 (de) * | 2001-07-23 | 2003-03-06 | Infineon Technologies Ag | Anordnung von Gräben in einem Halbleitersubstrat, insbesondere für Grabenkondensatoren |
EP2269618A1 (en) * | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer. |
MXPA05013879A (es) * | 2003-06-18 | 2006-06-27 | Genelux Corp | Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos. |
KR20090004839A (ko) * | 2005-09-07 | 2009-01-12 | 제네렉스, 인코포레이티드 | Gm-csf를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법 |
-
2007
- 2007-07-11 KR KR1020070069583A patent/KR20080084528A/ko not_active Application Discontinuation
-
2008
- 2008-03-17 WO PCT/US2008/057257 patent/WO2008113078A1/en active Application Filing
- 2008-03-17 JP JP2009553840A patent/JP5879024B2/ja active Active
- 2008-03-17 AU AU2008224811A patent/AU2008224811B2/en active Active
- 2008-03-17 DK DK08732358.0T patent/DK2136633T3/en active
- 2008-03-17 PT PT87323580T patent/PT2136633E/pt unknown
- 2008-03-17 CN CN200880014543A patent/CN101790310A/zh active Pending
- 2008-03-17 SI SI200831556T patent/SI2136633T1/sl unknown
- 2008-03-17 CA CA2681096A patent/CA2681096C/en active Active
- 2008-03-17 US US12/531,353 patent/US20100303714A1/en not_active Abandoned
- 2008-03-17 ES ES08732358.0T patent/ES2559684T3/es active Active
- 2008-03-17 HU HUE08732358A patent/HUE028362T2/en unknown
- 2008-03-17 BR BRPI0808736-9A2A patent/BRPI0808736A2/pt not_active Application Discontinuation
- 2008-03-17 CN CN201610872804.XA patent/CN106265765A/zh active Pending
- 2008-03-17 KR KR1020097021555A patent/KR20090122293A/ko active Search and Examination
- 2008-03-17 EP EP08732358.0A patent/EP2136633B1/en active Active
- 2008-03-17 KR KR1020157008176A patent/KR101869235B1/ko active IP Right Grant
- 2008-03-17 PL PL08732358T patent/PL2136633T3/pl unknown
-
2010
- 2010-06-25 HK HK10106289.5A patent/HK1139563A1/zh unknown
-
2014
- 2014-05-07 JP JP2014095947A patent/JP6147696B2/ja active Active
-
2016
- 2016-01-08 CY CY20161100008T patent/CY1117107T1/el unknown
- 2016-01-13 HR HRP20160041TT patent/HRP20160041T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0808736A2 (pt) | 2014-08-19 |
AU2008224811A1 (en) | 2008-09-18 |
CA2681096C (en) | 2015-09-01 |
PL2136633T3 (pl) | 2016-04-29 |
US20100303714A1 (en) | 2010-12-02 |
KR20090122293A (ko) | 2009-11-26 |
PT2136633E (pt) | 2016-02-22 |
CA2681096A1 (en) | 2008-09-18 |
JP2014193882A (ja) | 2014-10-09 |
CN101790310A (zh) | 2010-07-28 |
KR20150041181A (ko) | 2015-04-15 |
EP2136633A4 (en) | 2012-01-18 |
KR20080084528A (ko) | 2008-09-19 |
DK2136633T3 (en) | 2016-01-25 |
KR101869235B1 (ko) | 2018-07-11 |
HK1139563A1 (zh) | 2010-09-24 |
EP2136633B1 (en) | 2015-10-28 |
AU2008224811B2 (en) | 2013-09-26 |
HUE028362T2 (en) | 2016-12-28 |
JP2010521497A (ja) | 2010-06-24 |
HRP20160041T1 (hr) | 2016-02-12 |
SI2136633T1 (sl) | 2016-03-31 |
WO2008113078A1 (en) | 2008-09-18 |
EP2136633A1 (en) | 2009-12-30 |
JP5879024B2 (ja) | 2016-03-08 |
JP6147696B2 (ja) | 2017-06-14 |
ES2559684T3 (es) | 2016-02-15 |
CN106265765A (zh) | 2017-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1117107T1 (el) | Θεραπεια του καρκινου με τον ογκολυτικο ιο της δαμαλιτιδας | |
CY1122554T1 (el) | Συνδυασμοι φαρμακων | |
CY1124446T1 (el) | Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης | |
CY1120558T1 (el) | Ενας rdεν3/4δελτα 30(με),rdεν2/4δελτα30(με) ή rdεν1/4δελτα30(με) ανασυνδυασμενος χιμαιρικος ιος του δαγγειου πυρετου ο οποιος περιεχει μια 30 νουκλεοτιδιων διαγραφη (δελτα30) σε ενα τμημα της 3' αμεταφραστης περιοχης του γονιδιωματος ιου του δαγγειου πυρετου τυπου 4, οπου η εν λογω 30 νουκλεοτιδιων διαγραφη αντιστοιχει στην tl2 δομη στελεχους- βροχου | |
CY1117708T1 (el) | Ψευδοϊοι ιου θηλωματων για την ανιχνευση και τη θεραπεια ογκων | |
CY1118695T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
CY1108092T1 (el) | Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora | |
CY1123107T1 (el) | Θεραπεια δεοξυνουκλεοσιδιου για νοσους οι οποιες οφειλονται σε μη ισορροπημενες ομαδες νουκλεοτιδιων, οπου συμπεριλαμβανονται συνδρομα εξαντλησης μιτοχονδριακου dna | |
CY1119794T1 (el) | Ενωσεις αναστολεων ε-σελεκτινης | |
PH12015500485A1 (en) | Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer | |
CY1113757T1 (el) | Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων | |
CY1116288T1 (el) | Tnfsf απλης αλυσου μορια | |
CY1119893T1 (el) | Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων | |
CY1120421T1 (el) | Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων | |
ATE471334T1 (de) | Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs | |
DE60332355D1 (de) | Hla-a24-restringiertes krebsantigenpeptid | |
CY1114478T1 (el) | Παραγωγα πυριδαζινης ως αναστολεις smo | |
CY1116231T1 (el) | ΑΛΑΤΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 2,3-ΔIYΔPOΪMIΔAZO[l,2-C] ΚΙΝΑΖΟΛΙΝΗΣ | |
DK1771474T3 (da) | Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf | |
IS2994B (is) | Fosfónöt, monofosfónamidöt, bisfosfónamidöt til meðhöndlunar á veirusjúkdómum | |
CY1124391T1 (el) | Θεραπεια ανθεκτικης σε ιματινιμπη χρονιας μυελογενους λευχαιμιας που εχει τη μεταλλαξη 1457t>c στο bcrabl γονιδιο χρησιμοποιωντας την ενωση μποσουτινιμπη | |
CY1109964T1 (el) | Ετεροκυκλικοι δακτυλιοι συντηγμενοι με 1,4-διυδροπυριδινη, η διαδικασια παρασκευης τους, η χρηση και οι συνθεσεις που τους περιεχουν | |
Kim et al. | Anti-tumor effects by a synthetic chalcone compound is mediated by c-Myc-mediated reactive oxygen species production | |
DK1755659T3 (da) | Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation | |
ATE527998T1 (de) | Illudin-analoga als krebsmittel |